Want to see AU:NC6 full AI Analyst Report?
NC6 Stock Chart & Stats
AU$0.05
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.05
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.04 - AU$0.09
Previous CloseN/A
Volume1.00
Average Volume (3M)138.71K
Market Cap
AU$20.45M
Enterprise ValueAU$18.23M
Total Cash (Recent Filing)AU$274.97K
Total Debt (Recent Filing)AU$250.21K
Price to Earnings (P/E)―
Beta-0.17
Next Earnings
Aug 31, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding408,954,380
10 Day Avg. Volume179,263
30 Day Avg. Volume138,709
Financial Highlights & Ratios
PEG Ratio2.33
Price to Book (P/B)34.86
Price to Sales (P/S)0.00
P/FCF Ratio-12.58
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Sustainable Proprietary TechnologyNanollose’s microbial cellulose approach replaces tree/cotton sourcing with fermentation-grown materials. This gives a structural competitive edge if commercialised: lower environmental footprint aligns with long-term textile and biomaterial demand, enabling premium positioning and differentiation versus commodity fibers.
Low Financial LeverageLow reported debt materially reduces near-term solvency risk and preserves financial flexibility. For a pre-revenue biotech, limited leverage enables continued R&D and pilot projects without high fixed interest burdens, improving the company’s ability to pursue partnerships or scale if product-market fit is found.
Improving Cash Burn TrendAn improvement in free cash flow versus the prior year indicates operational or spending discipline gains. While still negative, a declining cash burn trajectory lengthens runway, reduces immediate financing pressure, and signals progress toward operational efficiency crucial for long-term viability.
Bears Say
Persistent UnprofitabilitySustained multi-year losses and deteriorating margins erode shareholder capital and prevent internal funding of growth. Persistent unprofitability forces repeated external financing, limits reinvestment capacity, and questions the business model’s ability to achieve durable unit economics at scale.
Revenue Collapsed To ZeroA drop to zero reported revenue is a stark signal of failed or paused commercialisation, lost contracts, or measurement/reporting gaps. Without recurring sales the company cannot validate demand or scale production, making future growth plans and capital efficiency highly uncertain.
Weak Cash Generation And Financing DependencyChronic negative operating cash flow means the business cannot self-fund development or commercialization. Continued reliance on external capital exposes operations to dilution, financing risk, and market access constraints — a structural vulnerability for a small biotech pursuing scale.
Nanollose Ltd. News
NC6 FAQ
What was Nanollose Ltd.’s price range in the past 12 months?
Nanollose Ltd. lowest share price was AU$0.04 and its highest was AU$0.09 in the past 12 months.
What is Nanollose Ltd.’s market cap?
Nanollose Ltd.’s market cap is AU$20.45M.
When is Nanollose Ltd.’s upcoming earnings report date?
Nanollose Ltd.’s upcoming earnings report date is Aug 31, 2026 which is in 60 days.
How were Nanollose Ltd.’s earnings last quarter?
Nanollose Ltd. released its earnings results on Feb 26, 2026. The company reported -AU$0.005 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.005.
Is Nanollose Ltd. overvalued?
According to Wall Street analysts Nanollose Ltd.’s price is currently Overvalued.
Does Nanollose Ltd. pay dividends?
Nanollose Ltd. does not currently pay dividends.
What is Nanollose Ltd.’s EPS estimate?
Nanollose Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Nanollose Ltd. have?
Nanollose Ltd. has 408,954,380 shares outstanding.
What happened to Nanollose Ltd.’s price movement after its last earnings report?
Nanollose Ltd. reported an EPS of -AU$0.005 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.389%.
Which hedge fund is a major shareholder of Nanollose Ltd.?
Currently, no hedge funds are holding shares in AU:NC6
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Nanollose Ltd. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
188.88%
12-Months-Change
Fundamentals
Return on Equity
-1964.93%
Trailing 12-Months
Asset Growth
-23.63%
Trailing 12-Months
Company Description
Nanollose Ltd.
Nanollose Limited is an Australian biomaterials enterprise dedicated to the research, development, and commercialization of microbial nanocellulose technology. Its product line features Nullarbor Fibre, an innovative lyocell fibre produced without relying on trees, and Jelli Grow, an eco-friendly substitute for seed germination and cultivating plants. These materials find applications across various sectors, including textiles, nonwoven fabrics, and other industries. Established in 2014, the company's headquarters are situated in Nedlands, Australia.
Technical Analysis
Prescient Therapeutics Limited
―
AnteoTech Ltd
―
Regeneus Ltd.
―
AdAlta Ltd.
―
Arovella Therapeutics Limited
―
Options Prices
Currently, No data available
---